Himuka AM Pharma Corp.
Drug discovery that contributes to the elimination of Unmet Medical Needs through research and development of drug discovery seeds of adrenomedullin (AM)
AM, which was discovered at the University of Miyazaki School of Medicine, has been suggested to be effective in intractable diseases such as ulcerative colitis and Crohn's disease. By further improving the AM, we are proceeding with the development of a more durable drug. Improved AM has been confirmed to be effective in animal experiments, and is currently being prepared for administration to humans. It is also expected to be applied to diseases such as cerebral infraction and suppressing the severity of pneumonia caused by COVID-19, and clinical research is progressing.
- Establishment Date
- February 2017
- Business
- Research and development of new drug discovery seeds for improved adrenomedullin
- CEO
- Representative Director Yuji Shinshiro
KII’s Perspective
As a company that applies AM, which is a bioactive substance found in Japan, to various disease areas, I hope that it will be commercialized.
KII growth support
Financing assistance, Business alliance support, Dispatch of board observers
